Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.30 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992303 | 0.82 | EP300 (0.42) | EP300KAT2BKAT8GLO1KEAP1 | |
| SCHEMBL4995428 | 0.71 | SLC22A12 (0.38) | EP300KAT2BKAT8GLO1KEAP1 | |
| SCHEMBL9688943 | 0.71 | JAK2 (0.46) | EP300KAT2BKAT8SLC22A12PARP14 | |
| SCHEMBL4987405 | 0.71 | ADRA1A (0.41) | — | |
| SCHEMBL2564270 | 0.70 | KEAP1 (0.38) | EP300KAT2BKAT8KEAP1 | |
| SCHEMBL2261006 | 0.70 | RXFP1 (0.39) | KDM4EHPGDHSD17B10ESR2 | |
| SCHEMBL4624216 | 0.70 | KEAP1 (0.46) | EP300KAT2BKAT8KEAP1KDM4E | |
| SCHEMBL12304314 | 0.69 | ALDH1A1 (0.32) | EP300KAT2BKAT8KEAP1SLC22A12 | |
| SCHEMBL2387578 | 0.69 | TRPV1 (0.33) | EP300KAT2BKAT8KEAP1KDM4E | |
| SCHEMBL14092111 | 0.69 | NR3C1 (0.39) | KEAP1KDM4EHPGDSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407980-B2 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407980-B2 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407980-B2 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1501817-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20040214875-A1 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC | 2004-10-28 | — | — | US | disclosed |
| US-6756395-B2 | CYCLIZATION OF N-(4-CYANOMETHYLPHENYL)METHANESULFONAMIDES WITH ETHYLENEDIAMINE TO FORM N-(4-IMIDAZOL-2-YLMETHYL)-PHENYL) -METHANESULFONAMIDES; INCONTINENCE, SEXUAL DYSFUNCTION, NASAL CONGESTION, AND CNS DISORDERS; ALPHA 1 ADRENERGIC AGONISTS | ROCHE PALO ALTO LLC | 2004-06-29 | — | — | US | disclosed |
| US-20030229130-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | ROCHE PALO ALTO LLC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003091236-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214875-A1 | Imidazolinylmethyl aralkylsulfonamides | RPS6KA1, RPS6KB1, RPS6KA6 | EP300 1605/4885KAT2B 2155/4885KAT8 2698/4885 |
| US-20030229130-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | RPS6KA1, RPS6KB1, RPS6KA6 | EP300 1605/4885KAT2B 2155/4885KAT8 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.